Stockscreener 앱 받기
0.90
9.09%
-0.09
시간 외 거래:
.94
0.04
+4.44%
전일 마감가:
$0.99
열려 있는:
$1
하루 거래량:
208.65K
Relative Volume:
0.76
시가총액:
$15.18M
수익:
-
순이익/손실:
$-52.53M
주가수익비율:
-0.2459
EPS:
-3.66
순현금흐름:
$-39.93M
1주 성능:
-21.05%
1개월 성능:
-46.75%
6개월 성능:
-38.36%
1년 성능:
-42.68%
1일 변동 폭
$0.8817
$1.00
1주일 범위
$0.8817
$1.2199
52주 변동 폭
$0.8817
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
명칭
Unity Biotechnology Inc
전화
(650) 416-1192
주소
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
UBX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
0.90 | 15.18M | 0 | -52.53M | -39.93M | -3.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-22 | 개시 | Rodman & Renshaw | Buy |
| 2023-11-16 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-01-04 | 업그레이드 | ROTH Capital | Neutral → Buy |
| 2021-11-10 | 업그레이드 | Mizuho | Neutral → Buy |
| 2021-06-28 | 업그레이드 | Citigroup | Sell → Buy |
| 2021-06-07 | 개시 | H.C. Wainwright | Buy |
| 2021-02-16 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-08-18 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-08-18 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2020-08-18 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-08-17 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-28 | 개시 | ROTH Capital | Buy |
| 2019-12-12 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-03-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-07 | 개시 | Mizuho | Buy |
| 2018-05-29 | 개시 | Citigroup | Buy |
| 2018-05-29 | 개시 | Goldman | Neutral |
| 2018-05-29 | 개시 | Morgan Stanley | Overweight |
모두보기
Unity Biotechnology Inc 주식(UBX)의 최신 뉴스
Unity Biotechnology stock hits 52-week low at $0.94 - Investing.com
Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock - Investing.com
Unity Biotechnology Executives Sell Shares for Tax Obligations - TradingView
What is HC Wainwright’s Estimate for UBX FY2026 Earnings? - Defense World
Unity Biotechnology (NASDAQ:UBX) Price Target Lowered to $4.00 at Chardan Capital - Defense World
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating - Investing.com Australia
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study - MSN
Unity Biotechnology price target lowered to $4 from $6 at Chardan - TipRanks
H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating By Investing.com - Investing.com South Africa
UNITY Biotechnology tanks on mixed results for eye disease drug - The Pharma Letter
Mizuho maintains Unity Biotechnology Outperform rating By Investing.com - Investing.com South Africa
Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating - Marketscreener.com
Mizuho maintains Unity Biotechnology Outperform rating - Investing.com India
Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC Wainwright - Defense World
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE - EIN News
Sector Update: Health Care Stocks Rise Late Afternoon - TradingView
Sector Update: Health Care - TradingView
Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint - Marketscreener.com
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
HC Wainwright Adjusts Unity Biotechnology Price Target to $4 From $8, Maintains Buy Rating - Marketscreener.com
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema - Yahoo Finance
Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls - Benzinga
Unity Biotechnology, Inc. Announces Topline Results from the ASPIRE Phase 2B Study in Diabetic Macular Edema - MarketScreener
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema - GlobeNewswire
New DME Treatment Matches Standard Care: Phase 2b Shows Promising Vision Gains - Stock Titan
China’s Plans for a $900 Billion Space Project, but Can It Catch Up to SpaceX? - The Globe and Mail
UNITY Biotechnology to Host Virtual Investor Event Featuring Phase 2b ASPIRE Study Results for UBX1325 in Diabetic Macular Edema - Nasdaq
UNITY Biotechnology to Host Virtual Investor Event to - GlobeNewswire
Key Phase 2b Data Coming: UNITY's DME Treatment Could Transform Eye Disease Care - Stock Titan
Where Will QuantumScape Stock Be in 3 Years? - The Globe and Mail
This Micro Cap Continues This Week's Dominance Amid New CEO Appointment - The Globe and Mail
RECONAFRICA ANNOUNCES ACCELERATION OF DRILLING INTO Q2 2025 AND A CORPORATE UPDATE - The Globe and Mail
3 Reasons to Avoid AIR and 1 Stock to Buy Instead - The Globe and Mail
This Media Stock Is Finding Serious Success Prior To Opening Bell - The Globe and Mail
Unity Biotechnology Reports 2024 Financial Results and Updates - MSN
Unity Biotechnology announces upcoming trial data and new board of directors member - Ophthalmology Times
Chardan Capital Has Bullish Outlook for UBX FY2025 Earnings - Defense World
HC Wainwright Has Strong Estimate for UBX FY2025 Earnings - Defense World
Analysts Issue Forecasts for UBX Q1 Earnings - Defense World
Unity Biotechnology (NASDAQ:UBX) Receives “Buy” Rating from Chardan Capital - Defense World
UNITY Biotechnology appoints Yehia Hashad to its board -March 10, 2025 at 10:40 am EDT - Marketscreener.com
Unity Biotechnology Appoints Dr. Yehia Hashad to Board - TipRanks
UNITY Biotechnology Appoints Industry Leader and - GlobeNewswire
UNITY Biotech Strengthens Board with CMO Appointment Before Key Trial Results - StockTitan
Buy Rating Reaffirmed for Unity Biotechnology Amid Promising Developments in DME Treatment - TipRanks
Unity Biotechnology reports Q4 EPS (50c) vs. (28c) last year - TipRanks
UNITY Biotechnology Reports Q4 and Full Year 2024 Financial Results and Anticipates ASPIRE Study Data on UBX1325 for Diabetic Macular Edema - Nasdaq
Unity Biotechnology, Inc. SEC 10-K Report - TradingView
UNITY Biotechnology, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - GlobeNewswire
Unity Biotechnology Inc (UBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):